Newsbenzinga
Syndax Says Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis Missed Primary Endpoint, Halts IPF Development
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…